CTIS2023-507363-20-00招募中1 期
PRO-101
Projenx Inc.0 个研究点目标入组 24 人开始时间: 2023年10月11日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A monocentric Phase I pivotal pharmacology study for the determination of the local and systemic exposure of locally applied Minocycline in periodontal pockets via a newly developed pharmaceutical formulation for the treatment of patients with recurrent or persistent periodontitisPeriodontitisCTIS2023-506126-36-00PerioTrap Pharmaceuticals GmbH24
进行中（未招募）
1 期
An Open-Label, Multicenter, Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1604 in Adults with Advanced MelanomaMetastatic MelanomaMedDRA version: 20.0Level: LLTClassification code: 10027481Term: Metastatic melanoma Class: 10029104CTIS2024-511949-19-00Sairopa B.V.44
招募中
1 期
A Phase 1/2a, First in Human, Open-Label, Multicenter, Dose Escalation Study with Expansion Cohorts to Evaluate the Safety, Tolerability, and Preliminary Activity of LB101 in Subjects with Advanced Solid TumorsCTIS2023-505576-29-00Centessa Pharmaceuticals UK Limited180
进行中（未招募）
1 期
Double-blind, randomized, placebo-controlled, pilot study to evaluate the safety, tolerability and efficacy of two doses of a conditioned medium from a co-culture of M2-macrophages and mesenchymal cells (PRS CK STORM) in the prevention of COVID-19-associated cytokine stormSARS-CoV-2 infectionMedDRA version: 23.0Level: LLTClassification code: 10084272Term: SARS-CoV-2 infection Class: 10021881CTIS2023-507700-32-00Peaches Biotech S.L.50
招募中
1 期
Phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC 1 in men with biochemical recurrence of prostate cancerCTIS2024-511430-12-00niversitaetsklinikum Tuebingen AöR56